MASLD/MASH: The New Names for Fatty Liver and What Bariatric Surgery Changes

Why the Name Changed

In 2023, a multi-society consensus process led to the terms NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) being replaced with MASLD and MASH. The change was made partly because the old names were defined by what the condition was not (alcohol-related) rather than what it is, and partly to better reflect the condition's close relationship with metabolic risk factors such as excess weight, type 2 diabetes, high blood pressure and abnormal lipid levels.

Under the new framework, a diagnosis of MASLD generally requires evidence of liver fat (steatosis) plus at least one cardiometabolic risk factor. MASH refers to the more advanced picture that includes liver inflammation and cell injury, which carries a higher risk of progressing to fibrosis over time.

Cardiometabolic risk factors used in this definition include excess weight or waist circumference, type 2 diabetes or prediabetes, high blood pressure, and abnormal cholesterol or triglyceride levels. A person can meet criteria for MASLD without having any liver-related symptoms at all, which is one reason the condition is frequently identified through routine blood tests or incidental imaging rather than through a patient reporting symptoms.

How the Condition Is Assessed

Initial assessment usually starts with blood tests, including liver enzymes, and calculation of a fibrosis risk score such as FIB-4, which combines age, liver enzymes and platelet count to estimate the likelihood of significant liver scarring.

Where FIB-4 or other findings suggest a need for further evaluation, elastography (a non-invasive test measuring liver stiffness, often via specialised ultrasound) can help estimate the degree of fibrosis without a biopsy in many cases. Liver biopsy remains the reference method in specific situations where non-invasive tests are inconclusive.

These scores and scans are screening and risk-stratification tools, not stand-alone diagnoses; their interpretation, and any decision about further testing or referral, should be made by the treating clinician in the context of the full clinical picture.

During an initial hepatology or gastroenterology review, questions typically cover alcohol intake, medication and supplement use, family history of liver disease, and the presence of related conditions such as diabetes or high cholesterol, alongside a physical examination looking for signs relevant to liver health. This broader picture, not the FIB-4 number alone, is what guides whether further imaging, referral, or simply a period of monitoring is the next step.

What Metabolic-Bariatric Surgery Can Contribute

In patients with obesity and MASLD or MASH who meet criteria for metabolic-bariatric surgery, published evidence — including randomised and long-term cohort data — shows that surgery can be associated with improvement in liver fat, and in some patients, improvement in inflammation and even fibrosis stage, alongside the broader metabolic improvements surgery can produce.

This is described in the literature as surgery contributing to histological improvement in suitable patients, not as a guaranteed resolution for every person. Individual outcomes vary, and patients with more advanced fibrosis at baseline appear less likely to see the same degree of reversal.

The mechanisms behind this improvement are thought to include reduced liver fat as overall body fat decreases, improved insulin sensitivity, and reductions in the inflammatory signals associated with excess visceral fat. Because these changes develop gradually over months to a couple of years, improvement in liver findings is generally assessed at intervals after surgery rather than expected immediately in the early post-operative period.

What Surgery Does Not Guarantee

Advanced fibrosis, once established, does not necessarily reverse completely even with substantial weight loss and metabolic improvement; some structural liver changes can persist. Surgery is one contributing intervention within a broader, sometimes lifelong, management plan rather than a stand-alone cure.

This is also why ongoing liver-related follow-up after surgery — including repeat blood tests or imaging when advised — is still generally recommended for patients with a pre-existing MASLD/MASH diagnosis, rather than assuming the issue is fully resolved after weight loss.

It is also worth setting realistic expectations about timeframe: while some improvement in liver enzymes can appear within months, meaningful change in fibrosis stage, when it occurs, is generally documented over a longer follow-up period, and not every study population shows the same degree of benefit, particularly where baseline disease was more advanced or other metabolic conditions were poorly controlled.

When Advanced Disease Changes the Pathway

For patients with advanced fibrosis or cirrhosis, current guidance emphasises a joint decision-making process involving hepatology or gastroenterology alongside the bariatric surgical team, since cirrhosis changes both the surgical risk profile and the expected benefit of intervention.

In this group, additional assessment (such as evaluating for portal hypertension or liver decompensation) is typically required before any surgical decision, and in some cases bariatric surgery may not be advisable or may need to be sequenced differently relative to liver-directed treatment.

For patients with compensated cirrhosis who are still considered for surgery, care is typically concentrated in centres with combined hepatology and bariatric surgical expertise, given the added complexity of perioperative planning, nutritional management and closer post-operative monitoring this group generally needs.

Alcohol, Medicines and Everyday Factors

Alcohol intake is relevant to liver health regardless of the MASLD/MASH label, and patients are generally advised to discuss their alcohol use openly with their treating clinician, since even amounts that might be considered modest can influence liver findings and management decisions.

Some medications are processed through the liver and may require dose adjustment or monitoring in the context of liver disease; always tell each prescriber about your liver history rather than assuming it is already known.

Everyday factors that are commonly discussed alongside MASLD/MASH management include gradual, sustained weight loss rather than very rapid loss, regular physical activity, and attention to sleep and stress, since all of these interact with the same metabolic pathways implicated in liver fat accumulation. None of these replace medical management where it is needed, but they are generally presented as complementary, ongoing parts of care rather than one-off actions.

Ongoing Follow-Up

Because MASLD/MASH is linked to broader metabolic health, ongoing management typically continues to address blood pressure, blood glucose and lipid levels alongside liver-specific monitoring, whether or not surgery has been performed.

The frequency of blood tests, elastography or specialist review is individualised based on baseline severity and response to treatment, and is set by the treating hepatology or gastroenterology team.

For patients who have had bariatric surgery, liver-related follow-up is generally coordinated alongside the other components of long-term post-surgical care, such as vitamin and mineral monitoring, so that a single set of visits can cover multiple aspects of ongoing health rather than requiring entirely separate appointment schedules where this is practical.

References

• PubMed 38851997 — MASLD/MASH nomenclature and clinical implications (opens in a new tab)
• EASL-EASD-EASO — Clinical practice guidelines on management of MASLD (opens in a new tab)
• PubMed 39560894 — Bariatric surgery and liver histology outcomes (opens in a new tab)
• PubMed 35076966 — Fibrosis assessment in metabolic liver disease (opens in a new tab)
• PubMed 37700494 — Bariatric surgery in patients with advanced liver disease (opens in a new tab)